
1. sci transl med. 2018 jan 24;10(425). pii: eaao1613. doi:
10.1126/scitranslmed.aao1613.

dimethyl fumarate potentiates oncolytic virotherapy nf-κb inhibition.

selman m(1)(2), ou p(1)(3), rousso c(1)(3), bergeron a(1)(3), krishnan r(1)(2),
pikor l(1), chen a(1), keller ba(1)(2), ilkow c(1)(2), bell jc(1)(2), diallo
js(4)(2).

author information: 
(1)centre innovative cancer research, ottawa hospital research institute,
ottawa, ontario k1h 8l6, canada.
(2)department biochemistry, microbiology immunology, university ottawa,
ottawa, ontario k1h 8m5, canada.
(3)faculty science, university ottawa, ottawa, ontario k1n 6n5, canada.
(4)centre innovative cancer research, ottawa hospital research institute,
ottawa, ontario k1h 8l6, canada. jsdiallo@ohri.ca.

resistance oncolytic virotherapy frequently associated failure of
tumor cells get infected virus. dimethyl fumarate (dmf), common
treatment psoriasis multiple sclerosis, also anticancer properties.
we show dmf various fumaric maleic acid esters (fmaes) enhance viral
infection cancer cell lines well human tumor biopsies several
oncolytic viruses (ovs), improving therapeutic outcomes resistant syngeneic
and xenograft tumor models. results durable responses, even models
otherwise refractory ov drug monotherapies. ability dmf enhance 
viral spread results ability inhibit type interferon (ifn)
production response, associated blockade nuclear
translocation transcription factor nuclear factor κb (nf-κb). study
demonstrates unconventional application u.s. food drug
administration-approved drugs biological agents result improved
anticancer therapeutic outcomes.

copyright © 2018 authors, rights reserved; exclusive licensee american
association advancement science. claim original u.s. government 
works.

doi: 10.1126/scitranslmed.aao1613 
pmid: 29367345  [indexed medline]

